# Proteinea

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proteinea

- Industry: Biotechnology
- Headquarters: Cairo, Egypt
- Website: www.proteinea.com
- Latest round: Seed (Feb 26, 2021)
- Investors on record: 2

## About

Based in Cairo, Egypt, Proteinea specializes in engineering innovative antibodies using proprietary AI technology, focusing on advanced therapeutic solutions for biopharmaceutical companies and research institutions.Founded in 2019 in Cairo, Egypt, Proteinea develops next-generation antibodies through AI-driven methods. The company has engaged in three funding deals, with the latest being a Grant of USD 0.09 mn led by Changelabs on February 26, 2021. The CEO is Mahmoud Eljendy, who co-founded the company alongside Abdulaziz Elgammal.Proteinea specializes in the engineering of next-generation antibodies through the application of proprietary AI models and computational tools. Their core product offerings focus on rationally designed antibody Fc domains that enable context-specific immune tuning, enhanced half-life, and targeted biodistribution. The company’s design frameworks integrate AI-driven predictions with therapeutic insights, aimed at unlocking differentiated immune functions. Proteinea's innovations are tailored for use in life-threatening diseases, catering primarily to biopharmaceutical companies and research institutions involved in the development of novel therapies. The geographical markets for these products extend across North America, Europe, and Asia, where they engage with a diverse clientele that includes biotech firms and academic research centers committed to advancing therapeutic modalities.Proteinea generates revenue through strategic partnerships and collaborations with biopharmaceutical companies and research institutions. The company’s business model often revolves around B2B transactions, focusing on the licensing of their proprietary technologies and custom antibody design services. Clients typically engage in contractual agreements that may involve milestone payments associated with research and development phases. This transaction structure allows for flexible pricing arrangements based on the specific services rendered, which may include comprehensive antibody engineering packages. While specific pricing details for these offerings are not disclosed, the structure emphasizes value-driven partnerships aimed at innovative therapeutic solutions in the biologics sector.Proteinea intends to leverage its recent Grant funding of USD 0.09 mn to enhance its research and development capabilities, focusing on launching new antibody products targeted for specific life-threatening diseases. The company aims to expand its market reach into Asia by 2023, enhancing its engagement with biotech firms and research institutions in this region. The recent funding will support these initiatives, facilitating the development of advanced therapeutic antibodies and strengthening Proteinea's position in the global market.

## Funding rounds

- Seed, Feb 26, 2021 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed